Pharmacogenetic of Salbutamol in Pediatric Asthma Crisis

N/ACompletedNCT02195258

Hôpital Necker-Enfants Malades95 enrolled

Overview

this study is designed to identify the genetic factors which can be implicated in the salbutamol responsiveness for asthmatic children in pediatric emergency department

Patients from 6 to 16 years old consulting for an acute asthma exacerbation and receiving a treatment by salbutamol according to the usual care could be recruited.Saliva from patient were collected using Oragen®.DNA OG-500 kit or swabs.Based on literature review, four SNP were chosen:ADBR2 gene), ARG gene, and GSNOR gene.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Asthma

Eligibility

Sex: ALLMin age: 6 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * children * 6-16 years old * asthmatic patients * consulting for an exacerbation in a pediatric emergency department * parental informed consent Exclusion Criteria: * comorbidity * peak flow no available * pneumonia

Locations (1)

Necker Enfants Malades Hospital

Paris, France

Outcomes

Primary Outcomes

pre- and post-bronchodilator FEV1 value (BDR = 100 x [post-FEV1 - pre-FEV1]/pre-FEV1)

comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator FEV1 value (BDR = 100 x \[post-FEV1 - pre-FEV1\]/pre-FEV1) between the different polymorphism

Time frame: Day 0

Secondary Outcomes

polymorphism on the response delay

Time frame: Day 0

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.